Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995–2015 Suggests an Adverse Environmental or Lifestyle Factor

Abstract

Objective To investigate detailed trends in malignant brain tumour incidence over a recent time period. Methods UK Office of National Statistics (ONS) data covering 81,135 ICD10 C71 brain tumours diagnosed in England (1995–2015) were used to calculate incidence rates (ASR) per 100k person–years, age–standardised to the European Standard Population (ESP–2013). Results We report a sustained and highly statistically significant ASR rise in glioblastoma multiforme (GBM) across all ages. The ASR for GBM more than doubled from 2.4 to 5.0, with annual case numbers rising from 983 to 2531. Overall, this rise is mostly hidden in the overall data by a reduced incidence of lower-grade tumours. Conclusions The rise is of importance for clinical resources and brain tumour aetiology. The rise cannot be fully accounted for by promotion of lower–grade tumours, random chance or improvement in diagnostic techniques as it affects specific areas of the brain and only one type of brain tumour. Despite the large variation in case numbers by age, the percentage rise is similar across the age groups, which suggests widespread environmental or lifestyle factors may be responsible. This article reports incidence data trends and does not provide additional evidence for the role of any particular risk factor.

Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973‐2014

“…Our results of rising trend of glioblastoma incidence and trend variations by glioma histology subtypes are in line with previous findings in the United States and European countries. [27][28][29][30] The observed distinct period and birth cohort effect patterns of glioblastoma and nonglioblastoma could be due to a number of histology-specific factors that dynamically affect the population. However, these histology-specific factors are largely unknown or postulated.…”

Ursolic acid inhibits cell migration and promotes JNK-dependent lysosomal associated cell death in Glioblastoma multiforme cells

“…Glioblastoma multiforme (GBM) is a highly malignant grade IV astrocytoma. It is considered to be the most biologically aggressive brain tumour and is associated with a post diagnosis survival rate of only 1 year (Philips et al, 2018). GBMs display attributes of various morphologies such as a heterogeneous mixture of cells that demonstrate varying degrees of cellular and nuclear polymorphism, making it difficult to clinically manage.…”

“…In an effort to overcome these issues, research groups have identified numerous naturally derived bioactive compounds (NDBC) known as phytochemicals that demonstrate anticancer activity when used alone or in combination for the treatment of cancer (Philips et al, 2018). Phytochemicals with anti-cancer properties are being assessed as precursors for new chemotherapeutic agents (Koldaş et al, 2015;Neto, 2007;Øverby et al, 2014;Sasidharan et al, 2011;H.…”

Baicalein-Enriched Fraction Extracted from Oroxylum indicum (L.) Benth. ex Kurz Leaves Exerts Antioxidant and Inhibitory Effects Against Glioblastoma Multiforme

“…The rapid tumour growth is mainly related to deregulation of the G1/S checkpoint in the cell cycle and the occurrence of multiple genetic abnormalities of tumor cells [2,3]. However, the actual causes of these brain tumors in adults remain largely unknown [4]. At present, standard clinical treatment for GBM relies on surgery and chemo-radiation therapies [5].…”